Profusa Inc (PFSA)

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Profusa Announces 1-for-25 Reverse Stock Split

BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq:...

Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts

BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company...

Form 8-K - Current report

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company...

Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting

BERKELEY, CA, June 10, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a...

Profusa Announces Listing Transfer to The Nasdaq Capital Market

BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) --  Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a ...

Profusa Receives Favorable Nasdaq Listing Determination

BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a ...

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research...

Form EFFECT - Notice of Effectiveness